| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5293 | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2761 | 2020 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1331 | 2021 |
| COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study VJ Hall, S Foulkes, A Saei, N Andrews, B Oguti, A Charlett, E Wellington, ... The Lancet 397 (10286), 1725-1735, 2021 | 758 | 2021 |
| Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... The Lancet 397 (10282), 1351-1362, 2021 | 740 | 2021 |
| SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) VJ Hall, S Foulkes, A Charlett, A Atti, EJM Monk, R Simmons, E Wellington, ... The Lancet 397 (10283), 1459-1469, 2021 | 672 | 2021 |
| Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised … X Liu, RH Shaw, ASV Stuart, M Greenland, PK Aley, NJ Andrews, ... The Lancet 398 (10303), 856-869, 2021 | 489 | 2021 |
| Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells EA Clutterbuck, R Lazarus, LM Yu, J Bowman, EAL Bateman, L Diggle, ... Journal of Infectious Diseases 205 (9), 1408-1416, 2012 | 300 | 2012 |
| Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) A Flaxman, NG Marchevsky, D Jenkin, J Aboagye, PK Aley, B Angus, ... The Lancet 398 (10304), 981-990, 2021 | 269 | 2021 |
| Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a … ASV Stuart, RH Shaw, X Liu, M Greenland, PK Aley, NJ Andrews, ... The Lancet 399 (10319), 36-49, 2022 | 214 | 2022 |
| The risk of metachronous neoplasia in patients with serrated adenoma R Lazarus, OE Junttila, TJ Karttunen, MJ Mäkinen American journal of clinical pathology 123 (3), 349-359, 2005 | 177 | 2005 |
| Oxford COVID Vaccine Trial Group Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... Lancet 397 (10269), 99-111, 2021 | 133 | 2021 |
| Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a … R Lazarus, S Baos, H Cappel-Porter, A Carson-Stevens, M Clout, ... The Lancet 398 (10318), 2277-2287, 2021 | 132 | 2021 |
| A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults R Lazarus, E Clutterbuck, LM Yu, J Bowman, EA Bateman, L Diggle, ... Clinical Infectious Diseases 52 (6), 736-742, 2011 | 129 | 2011 |
| Severity of Omicron (B. 1.1. 529) and Delta (B. 1.617. 2) SARS-CoV-2 infection among hospitalised adults: A prospective cohort study in Bristol, United Kingdom C Hyams, R Challen, R Marlow, J Nguyen, E Begier, J Southern, J King, ... The Lancet Regional Health–Europe 25, 2023 | 103 | 2023 |
| Oxford COVID Vaccine Trial Group Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised … PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... Lancet 396 (10249), 467-478, 2020 | 68 | 2020 |
| Safety and immunogenicity report from the com-COV study–a single-blind randomised non-inferiority trial comparing heterologous and homologous prime-boost schedules with an … X Liu, RH Shaw, ASV Stuart, M Greenland, T Dinesh, ... | 58 | 2021 |
| COVID-19 Genomics UK consortium; AMPHEUS Project KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... Oxford COVID-19 Vaccine Trial Group. Efficacy of ChAdOx1 nCoV-19 (AZD1222 …, 2021 | 52 | 2021 |
| Efficacy, safety, and immunogenicity of a booster regimen of Ad26. COV2. S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled … K Hardt, A Vandebosch, J Sadoff, M Le Gars, C Truyers, D Lowson, ... The Lancet Infectious Diseases 22 (12), 1703-1715, 2022 | 47 | 2022 |
| A cross-sectional observational study of pneumococcal carriage in children, their parents, and older adults following the introduction of the 7-valent pneumococcal conjugate … M Hamaluba, R Kandasamy, S Ndimah, R Morton, M Caccamo, ... Medicine 94 (1), e335, 2015 | 41 | 2015 |
